Linear Solution-Phase Synthesis of Wnt Hexapeptide Foxy-5
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current solid phase peptide synthesis methods for producing Foxy-5, a formylated WNT5A-derived hexapeptide, are not scalable for large-scale clinical and commercial production, leading to high costs and limitations in producing larger batches for further clinical studies and eventual commercial purposes.
Innovation Solution
A linear solution-phase method for synthesizing Foxy-5 and its derivatives, involving sequential coupling of protected amino acid derivatives, which allows for efficient assembly and purification, reducing raw material costs and enabling adaptability to commercial scale-up, with specific steps including telescoped reactions and careful protection group management to maintain high chemical and optical purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If classical solid phase peptide synthesis (SPPS) is used to produce Foxy-5, then the peptide can be synthesized with controlled purity, but the method is not scalable for large-scale production and results in high costs
Solution Approach 1:
The patent replaces the mechanical solid-phase synthesis system with a solution-phase chemical synthesis system. Instead of using resin beads and solid support mechanisms, the invention employs traditional solution-phase coupling reactions where amino acids are coupled in solution, allowing for scalable production while maintaining purification control through established chemical purification techniques
Solution Approach 2:
The patent changes the physical state parameter from solid-phase to solution-phase synthesis. This fundamental parameter change enables the reaction system to be scaled up using conventional solution chemistry equipment and procedures, while the purification steps maintain the required peptide purity through controlled chemical separation processes
2Manufacturing precision
If classical solid phase peptide synthesis (SPPS) is used to produce Foxy-5, then the peptide can be synthesized with controlled purity, but raw material costs are high
Solution Approach 1:
The patent employs readily available, inexpensive solution-phase reagents and solvents that can be easily obtained and disposed of, replacing the expensive specialized resins and solid-phase reagents. The solution-phase approach uses conventional chemical reagents that are much more cost-effective for large-scale production while achieving the same purification outcomes through standard chemical separation techniques
3Manufacturing precision
If a linear 1+1+1+1+1+1 route is used in SPPS to assemble Foxy-5, then the peptide sequence can be constructed step-by-step, but the process is cumbersome and not adaptable to commercial scale-up
Solution Approach 1:
The patent replaces the mechanical step-by-step solid-phase assembly process with a solution-phase chemical synthesis approach. The linear coupling sequence is maintained for precision, but the execution occurs in solution using conventional peptide coupling chemistry, which is inherently more adaptable to commercial scale-up as it uses standard chemical reaction vessels and procedures rather than specialized solid-phase synthesis equipment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a scalable and cost-effective route for producing Foxy-5, enabling the production of larger batches with high chiral purity, suitable for Good Manufacturing Practice (GMP) standards, addressing the limitations of traditional solid phase synthesis.
Implementation Method 1
sequential coupling of protected amino acid derivatives
Implementation Method 2
sequential coupling of protected amino acid derivatives, which allows for efficient assembly
Implementation Method 3
careful protection group management to maintain high chemical and optical purity
Implementation Method 4
allows for efficient assembly and purification
Data Source
AI summary
The present disclosure relates generally to the field of polypeptide synthesis, and more particularly, to a linear solution phase synthesis of the Wnt hexapeptide Foxy-5 and protected derivatives and peptide fragments thereof.